Loading...

VXN

VX

EVAXION A

(EVAX)

2024 6-K

Business Update

7 May '26

Business Update Announced

4 May '26

Management Change

27 Apr '26

Annual Meeting Results

22 Apr '26

Vaccine Precision Report

17 Apr '26

AI-Immunology Update

17 Apr '26

Annual Meeting Update

16 Apr '26

Cancer Vaccine Update

7 Apr '26

AI Vaccine Presentation

30 Mar '26

Annual Meeting Notice

19 Mar '26

Annual Meeting Notice

19 Mar '26

Event Announcement

17 Mar '26

Business Update

5 Mar '26

Annual Report Filing

5 Mar '26

Business Update Ahead

2 Mar '26

Warrant Grants

27 Feb '26

AI Expansion News

13 Jan '26

Company Milestones Announced

7 Jan '26

Collaboration Update

19 Dec '25

Share Offer Update

10 Dec '25

Cancer Vaccine Update

8 Dec '25

Positive Vaccine Data

20 Nov '25

Capital Increase

18 Nov '25

Financial Calendar Announced

12 Nov '25

New Vaccine Data

7 Nov '25

Business Update

6 Nov '25

New Vaccine Development

3 Nov '25

Correction Announcement

31 Oct '25

Business Update Announcement

31 Oct '25

Capital Increase Announcement

30 Oct '25

Funding Announcement

30 Oct '25

Management Change

27 Oct '25

Capital Increase

17 Oct '25

Positive Trial Results

17 Oct '25

Cancer Vaccine Update

14 Oct '25

AI Vaccine Expansion

8 Oct '25

New Cancer Vaccine Data

6 Oct '25

Vaccine Licensing Agreement

25 Sep '25

Conference Presentations

27 Aug '25

Business Update

14 Aug '25

Q2 2025 Financials

14 Aug '25

Business Update Announcement

11 Aug '25

Clinical Data Release

25 Jul '25

Debt Settlement Agreement

17 Jul '25

Debt Conversion Agreement

11 Jul '25

Management Changes

2 Jul '25

Vaccine Program Expansion

25 Jun '25

Funding Announcement

3 Jun '25

Business Update

27 May '25

Business Update Notification

23 May '25

Cancer Vaccine Trial

22 May '25

Annual Meeting Summary

5 May '25

Warrant Updates

29 Apr '25

Key Vaccine Results

28 Apr '25

Event Announcement

10 Apr '25

Annual Meeting Notice

7 Apr '25

Business Update

1 Apr '25

Business Update Announcement

27 Mar '25

Financing Update

26 Mar '25

New Phase 2 Data

25 Mar '25

Conference Presentations

4 Mar '25

Trial Extension Announcement

25 Feb '25

Compliance Confirmation

14 Feb '25

Capital Increase Update

12 Feb '25

Funding Announcement

31 Jan '25

Public Offering Announcement

30 Jan '25

Compliance Extension Granted

28 Jan '25

Capital Increase

27 Jan '25

Capital Restructuring

21 Jan '25

Trial Completion

15 Jan '25

ADS Ratio Change

14 Jan '25

ADS Ratio Change

10 Jan '25

Capital Increase

7 Jan '25

ADS Ratio Change

30 Dec '24

Extraordinary Meeting Notice

26 Dec '24

Debt Conversion Agreement

17 Dec '24

Cancer Vaccine Concept

12 Dec '24

2025 Milestones Announced

9 Dec '24

Vaccine Presentation

3 Dec '24

Delisting Appeal

13 Nov '24

Share Capital Increase

13 Nov '24

Positive Vaccine Data

13 Nov '24

Business Update

31 Oct '24

Business Update Announcement

28 Oct '24

AI-Immunology Validation

9 Oct '24

Clinical Data Update

4 Oct '24

Capital Increase Report

3 Oct '24

License Agreement Signed

1 Oct '24

Vaccine Partnership Expansion

26 Sep '24

Management Changes

20 Sep '24

AI Vaccine Platform

19 Sep '24

Cancer Vaccine Update

16 Sep '24

Cancer Vaccine Update

9 Sep '24

Vaccine Progress Report

9 Sep '24

Capital Increase

19 Aug '24

Business Update

14 Aug '24

Q2 Financial Results

14 Aug '24

Business Update Announcement

12 Aug '24

Clinical Study Update

8 Aug '24

Management Change

2 Aug '24

Event Announcement

16 Jul '24

Board Resignation

3 Jul '24

Shareholder Update

3 Jul '24

License Agreement Update

2 Jul '24

Patent Agreement Reached

2 Jul '24

Patent Application Update

26 Jun '24

Warrant Amendment

24 Jun '24

Listing Compliance Update

18 Jun '24

Cancer Vaccine Update

17 Jun '24

Warrant Grant Update

7 Jun '24

Warrant Granting

3 Jun '24

Positive Vaccine Data

3 Jun '24

Business Update

28 May '24

Warrant Amendment

24 May '24

Press Release Update

23 May '24

Nasdaq Notification

10 May '24

Annual Meeting Results

25 Apr '24

Phase 2 Trial Update

17 Apr '24

Vaccine Development Update

2 Apr '24

Annual Meeting Notice

29 Mar '24

Business Update Report

27 Mar '24

R&D Day Announcement

19 Mar '24

Capital Increase

13 Mar '24

R&D Day Announcement

29 Feb '24

Vaccine Collaboration Success

20 Feb '24

Share Capital Increase

7 Feb '24

Compliance Regained

7 Feb '24

Public Offering Completed

6 Feb '24

Securities Purchase Agreement

5 Feb '24

Public Offering Announced

1 Feb '24

Share Sale Announcement

26 Jan '24

6-K Filing Update

24 Jan '24

ADS Ratio Change

22 Jan '24

Funding Update

12 Jan '24

Extraordinary Meeting Notice

10 Jan '24

ADS Ratio Change

8 Jan '24

External Links:

SEC

On June 17, 2024, Evaxion Biotech A/S announced a press release highlighting a 67% objective response rate for their AI-designed personalized cancer vaccine EVX-01 in metastatic melanoma, published in a leading medical journal. This significant progress positions the company well in the biotech sector, reflecting positive sentiment.

AI Assistant

EVAXION A

2024

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.